Advertisement

Psychopharmacology: A Brief Overview of Its History

  • Paul FoleyEmail author
Living reference work entry
  • 4 Downloads

Abstract

People have used diverse types of drugs and other preparations to ease their physical pain and mental distress for thousands of years. The search for new, more effective drugs gathered pace during the nineteenth century, before a confluence of factors culminated in the birth of modern psychopharmacology in the early 1950s, heralded by the discovery of the first neuroleptic and antidepressant agents. The rapid expansion of the number of options for psychopharmacotherapy, particularly between 1950 and 1980, has radically transformed both basic and clinical neuroscience.

References

  1. Abdelgadir IS, Gordon MA, Akobeng AK. Melatonin for the management of sleep problems in children with neurodevelopmental disorders: a systematic review and meta-analysis. Arch Dis Child. 2018;103:1155–62.PubMedCrossRefGoogle Scholar
  2. Aisen PS, Cummings J, Schneider LS. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006395.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Aita JF, Aita JA, Aita VA. 7-Up anti-acid lithiated lemon soda or early medicinal use of lithium. Nebr Med J. 1990;75:277–80.PubMedGoogle Scholar
  4. Angrist BM. The neurobiologically active benzamides and related compounds: some historical aspects. In: Rotrosen J, Stanley M, editors. The benzamides: pharmacology, neurobiology, and clinical effects (Advances in biochemical psychopharmacology; 35). New York: Raven Press; 1982. pp. 1–6.Google Scholar
  5. Ashok AH, Marques TR, Jauhar S, Nour MM, Goodwin GM, Young AH, Howes OD. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry. 2017;22:666–79.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Atkin T, Comai S, Gobbi G. Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery. Pharmacol Rev. 2018;70:197–245.PubMedCrossRefGoogle Scholar
  7. Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev. 2017;34:10–22.PubMedCrossRefGoogle Scholar
  8. Awouters FH, Lewi PJ. Forty years of antipsychotic drug research – from haloperidol to paliperidone – with Dr. Paul Janssen. Arzneimittelforschung. 2007;57:625–32.PubMedGoogle Scholar
  9. Ayd FJ. Fatal hyperpyrexia during chlorpromazine therapy. J Clin Exp Psychopathol. 1956;17:189–92.PubMedGoogle Scholar
  10. Baldwin DS, Anderson IM, Nutt DJ, Christer A, Bandelow B, den Boer JA, Christmas DM, Davies S, Fineberg N, Lidbetter N, Malizia A, McCrone P, Nabarro D, O’Neill C, Scott J, van der Wee N, Wittchen H-U. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28:403–39.PubMedCrossRefGoogle Scholar
  11. Balme R. Early medicinal uses of bromides. J R Coll Physicians Edinb. 1976;10:205–8.Google Scholar
  12. Ban TA. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat. 2007;3:495–500.Google Scholar
  13. Barbara J-G. History of psychopharmacology: from functional restitution to functional enhancement. In: Clausen J, Levy N, editors. Handbook of neuroethics. Dordrecht: Springer; 2015. pp. 489–504.Google Scholar
  14. Barroso MS. The hellebore, the plant beloved by the Greeks: the reasons behind a myth. Vesalius. 2015;21:30–7.Google Scholar
  15. Battleday RM, Brem AK. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: a systematic review. Eur Neuropsychopharmacol. 2015;25:1865–81.PubMedCrossRefGoogle Scholar
  16. Baumeister AA. The chlorpromazine enigma. J Hist Neurosci. 2013;22:14–29.PubMedCrossRefGoogle Scholar
  17. Baumeister AA, Francis JL. Historical development of the dopamine hypothesis of schizophrenia. J Hist Neurosci. 2002;11:265–77.PubMedCrossRefGoogle Scholar
  18. Baumeister AA, Hawkins MF. Continuity and discontinuity in the historical development of modern psychopharmacology. J Hist Neurosci. 2005;14:199–209.PubMedCrossRefGoogle Scholar
  19. Baumeister AA, Hawkins MF, Uzelac SM. The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis. J Hist Neurosci. 2003;12:207–20.PubMedCrossRefGoogle Scholar
  20. Becker PM, Somiah M. Non-benzodiazepine receptor agonists for insomnia. Sleep Med Clin. 2015;10:57–76.PubMedCrossRefGoogle Scholar
  21. Bennett MR. Monoaminergic synapses and schizophrenia: 45 years of neuroleptics. J Psychopharmacol. 1998;12:289–304.PubMedCrossRefGoogle Scholar
  22. Berger H. Zur Pathogenese des katatonischen Stupors. Münch med Wschr. 1921;68:448–50.Google Scholar
  23. Beringer K. Der Meskalinrausch: Seine Geschichte und Erscheinungsweise. Berlin: Julius Springer; 1927.CrossRefGoogle Scholar
  24. Bleuler E. Die Kritiken der Schizophrenien. Zschr f d ges Neurol u Psychiat. 1914;22:19–44.CrossRefGoogle Scholar
  25. Bossong F. Erinnerung an Roland Kuhn (1912–2005) und 50 Jahre Imipramin. Nervenarzt. 2008;79:1080–6.PubMedCrossRefGoogle Scholar
  26. Braslow JT. History and evidence-based medicine: lessons from the history of somatic treatments from the 1900s to the 1950s. Ment Health Serv Res. 1999;1:231–40.PubMedCrossRefGoogle Scholar
  27. Brouillot P, Broussolle P, Greffe J, Guyotat J, Lambert P, Lemoine P. The birth of psychopharmacotherapy: explorations in a new world 1952–1968. In: Healy D, editor. The psychopharmacologists, vol. 3. London: Arnold; 2000. pp. 1–54.Google Scholar
  28. Brown WA, Rosdolsky M. The clinical discovery of imipramine. Am J Psychiatr. 2015;172:426–9.PubMedCrossRefGoogle Scholar
  29. Butler TC. The introduction of chloral hydrate into medical practice. Bull Hist Med. 1970;44:168–72.PubMedGoogle Scholar
  30. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia – implications for schizophrenia and Parkinson’s disease. Trends Neurosci. 1990;13:272–6.PubMedCrossRefGoogle Scholar
  31. Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry. 1980;41:79–83.PubMedGoogle Scholar
  32. Carpenter WT, Davis JM. Another view of the history of antipsychotic drug discovery and development. Mol Psychiatry. 2012;17:1168–73.PubMedCrossRefGoogle Scholar
  33. Castro Caldas A, Teodoro T, Ferreira JJ. The launch of opicapone for Parkinson’s disease: negatives versus positives. Expert Opin Drug Saf. 2018;17:331–7.PubMedCrossRefGoogle Scholar
  34. Chiarello RJ, Cole JO. The use of psychostimulants in general psychiatry: a reconsideration. Arch Gen Psychiatry. 1987;44:286–95.PubMedCrossRefGoogle Scholar
  35. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357–66.PubMedPubMedCentralCrossRefGoogle Scholar
  36. Clouston TS. Clinical lectures on mental diseases. London: J. & A. Churchill; 1887.Google Scholar
  37. Colonna L. Antideficit properties of neuroleptics. Acta Psychiatr Scand. 1994;89(Suppl. 380):77–82.CrossRefGoogle Scholar
  38. Contestabile A. The history of the cholinergic hypothesis. Behav Brain Res. 2011;221:334–40.PubMedCrossRefGoogle Scholar
  39. Coppen A. The biochemistry of affective disorders. Br J Psychiatry. 1967;113:1237–64.PubMedCrossRefGoogle Scholar
  40. Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A. Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019;29:971–85.PubMedCrossRefGoogle Scholar
  41. Costentin J. Une nouvelle approche de la prise en charge de la schizophrénie: les agonistes partiels des récepteurs D2 de la dopamine. Ann Pharm Fr. 2009;67:310–9.PubMedCrossRefGoogle Scholar
  42. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007;18:39–60.PubMedCrossRefGoogle Scholar
  43. D’Abreu A, Akbar U, Friedmanac JH. Tardive dyskinesia: epidemiology. J Neurol Sci. 2018;389:17–20.PubMedCrossRefGoogle Scholar
  44. Dale E, Bang-Andersen B, Sánchez C. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochem Pharmacol. 2015;95:81–97.PubMedCrossRefGoogle Scholar
  45. Davis KL, Kahn R, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatr. 1991;148:1474–86.PubMedCrossRefGoogle Scholar
  46. Debreyne. Des vertus thérapeutiques de la belladone. Paris: J.-B. Ballière; 1852.Google Scholar
  47. Degkwitz R. Leitfaden der Psychopharmakologie für Klinik und Praxis. Stuttgart: Wissenschaftliche Verlags-Gesellschaft; 1967.Google Scholar
  48. Delay J, Deniker P. Trente-huit cas de psychoses traitées par la cure prolongée et continue de 4560 R. P. C. R. In: Congrès des médecins aliénistes et neurologistes de France et des pays de langue française, Le session, Luxembourg, 21–27 juillet 1952. Paris: Masson & Cie; 1952. pp. 503–13.Google Scholar
  49. Delay J, Pichot P, Lemperiere T, Glissalde B, Peigne F. Le neuroleptique majeur non phenothiazinique et non reserpinique, l’haloperidol, dans le traitement es psychoses [Séance du 21 Decembre 1959]. Annales médico-psychologiques (Paris). 1960;118:145–52.Google Scholar
  50. Denicoff KD, Frye MA, Dunn RT, Leverich GS, Osuch E, Speer A. A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th century. Neuropsychobiology. 1998;38:152–66.PubMedCrossRefGoogle Scholar
  51. Deniker P. From chlorpromazine to tardive dyskinesia (brief history of the neuroleptics). Psychiatr J Univ Ott. 1989;14:253–9.PubMedGoogle Scholar
  52. Dormandy T. Opium: reality’s dark dream. New Haven: Yale University Press; 2012.Google Scholar
  53. Douchamps V, Mathis C. A second wind for the cholinergic system in Alzheimer’s therapy. Behav Pharmacol. 2017;28:112–23.PubMedCrossRefGoogle Scholar
  54. Dub LA, Lurie LA. Use of benzedrine in the depressed phase of the psychotic state. Ohio State Med J. 1939;35:39–45.Google Scholar
  55. Dundee JW, McIlroy PDA. The history of the barbiturates. Anaesthesia. 1982;37:726–34.PubMedCrossRefGoogle Scholar
  56. Duval AM, Goldman D. The new drugs (chlorpromazine & reserpine): administrative aspects. Ment Hosp. 1956:7, 30–34. (reprinted: Psychiatric Services 2000; 2051:2327–2331)Google Scholar
  57. Eadie MJ. Convulsive ergotism: epidemics of the serotonin syndrome? Lancet Neurol. 2003;2:429–34.PubMedCrossRefGoogle Scholar
  58. Eadie MJ. Sir Charles Locock and potassium bromide. J R Coll Physicians Edinb. 2012;42:274–9.PubMedCrossRefGoogle Scholar
  59. Fangmann P, Assion H-J, Juckel G, González CÁ, López-Muñoz F. Half a century of antidepressant drugs. On the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: tricyclics and tetracyclics. J Clin Psychopharmacol. 2008;28:1–4.PubMedCrossRefGoogle Scholar
  60. Fink M. Meduna and the origins of convulsive therapy. Am J Psychiatr. 1984;141:1034–41.PubMedCrossRefGoogle Scholar
  61. Fink M. Catatonia: a syndrome appears, disappears, and is rediscovered. Can J Psychiatr Rev Can Psychiatr. 2009;54:437–45.CrossRefGoogle Scholar
  62. Flechsig P. Über eine neue Behandlungsmethode der Epilepsie. Neurol Centralbl. 1893;12:229–31.Google Scholar
  63. Foley PB. Beans, roots and leaves. A history of the chemical therapy of parkinsonism. Marburg: Tectum Verlag; 2003.Google Scholar
  64. Foley P. Succi nervorum: a brief history of neurochemistry. J Neural Transm Suppl. 2008;72:5–15.CrossRefGoogle Scholar
  65. Foley PB. Sons and daughters beyond your control: episodes in the prehistory of the attention deficit/hyperactivity syndrome. Atten Defic Hyperact Disord. 2014;6:125–51.PubMedCrossRefGoogle Scholar
  66. Foley PB. Encephalitis lethargica. The mind and brain virus. New York: Springer; 2018.CrossRefGoogle Scholar
  67. Folin O. Some metabolism studies. With special reference to mental disorders. Am J Insanity. 1904;60:699–732.Google Scholar
  68. Fond G, Micoulaud-Franchi J-A, Brunel L, Macgregor A, Miot S, Lopez R, Richieri R, Abbar M, Lancon C, Repantis D. Innovative mechanisms of action for pharmaceutical cognitive enhancement: a systematic review. Psychiatry Res. 2015;229:12–20.PubMedCrossRefGoogle Scholar
  69. Freeman W. Psychochemistry: some physicochemical factors in mental disorders. J Am Med Assoc. 1931;97:293–6.CrossRefGoogle Scholar
  70. Freud S. Abriß der Psychoanalyse (aus dem Nachlaß). Internationalen Zeitschrift für Psychoanalyse und Imago. 1940;25:7–67.Google Scholar
  71. Freyhan FA. Comments on the biological and psychopathological basis of individual variation in chlorpromazine therapy. L’Encéphale. 1956;45:913–9.PubMedGoogle Scholar
  72. Freyhan FA. Clinical effectiveness of Tofranil in the treatment of depressive psychoses. Can Psychiatr Assoc J. 1959;4(Suppl):S86–99.CrossRefGoogle Scholar
  73. Froestl W, Pfeifer A, Muhs A. Cognitive enhancers (nootropics). Update 2014. J Alzheimers Dis. 2014;42:1–68,961–1019,1079–1149PubMedCrossRefGoogle Scholar
  74. Gjessing R. Beiträge zur Kenntnis der Pathophysiologie periodisch katatoner Zustände. IV. Mitteilung. Versuch einer Ausgleichung der Funktionsstörungen. Arch Psychiatr Nervenkr. 1939;109:525–95.CrossRefGoogle Scholar
  75. Granger B, Albu S. The haloperidol story. Ann Clin Psychiatry. 2005;17:137–40.PubMedCrossRefGoogle Scholar
  76. Griesinger W. Die Pathologie und Therapie der psychischen Krankheiten für Ärzte und Studirende. 2nd ed. Stuttgart: Adolph Krabbe; 1861.Google Scholar
  77. Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8:303–18.PubMedPubMedCentralCrossRefGoogle Scholar
  78. Haenel T. Jakob Klaesi: Schlafkur und Antieidodiathese. Gesnerus. 1979;36:246–65.PubMedGoogle Scholar
  79. Hanzlik PJ. Purkinje’s pioneer self-experiments in psychopharmacology. Cal West Med. 1938;49:140–2.Google Scholar
  80. Hare EH, McCance C, McCormick WO. Imipramine and “Drinamyl” in depressive illness: a comparative trial. Br Med J. 1964;1:818.PubMedPubMedCentralCrossRefGoogle Scholar
  81. Harley J. The old vegetable neurotics. Hemlock, opium, belladonna and henbane. Their physiological action and therapeutical use alone and in combination. Being the Gulstonian lectures of 1868, extended and including a complete examination of the active constituents of opium. London: Macmillan and Co.; 1869.Google Scholar
  82. Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present – a pharmacological and clinical perspective. J Psychopharmacol. 2013;27:479–96.PubMedPubMedCentralCrossRefGoogle Scholar
  83. Healy D. The creation of psychopharmacology. Cambridge, MA: Harvard University Press; 2002.CrossRefGoogle Scholar
  84. Herzberg D. Blockbusters and controlled substances: Miltown, Quaalude, and consumer demand for drugs in postwar America. Stud Hist Phil Biol Biomed Sci. 2011;42:415–26.CrossRefGoogle Scholar
  85. Hökfelt T. Looking at neurotransmitters in the microscope. Prog Neurobiol. 2010;90:101–18.PubMedCrossRefGoogle Scholar
  86. Hollister LE. The pre-benzodiazepine era. J Psychoactive Drugs. 1983;15:9–13.PubMedCrossRefGoogle Scholar
  87. Howland RH. Methylene blue: the long and winding road from stain to brain. J Psychosoc Nurs Ment Health Serv. 2016;10(9):21–4, (10) 21–26Google Scholar
  88. Huehnerfeld J. The hematoporphyrin treatment of melancholia and endogenous depression. Am J Psychiatr. 1936;92:1323–30.CrossRefGoogle Scholar
  89. Ilieva IP, Hook CJ, Farah MJ. Prescription stimulants’ effects on healthy inhibitory control, working memory, and episodic memory: a meta-analysis. J Cogn Neurosci. 2015;27:1069–89.PubMedCrossRefGoogle Scholar
  90. Jaspers K. Allgemeine Psychopathologie. 4th ed. Berlin/Heidelberg: Springer; 1946.CrossRefGoogle Scholar
  91. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079–87.PubMedCrossRefGoogle Scholar
  92. Kalischer S. Medikamentöse Therapie. In: Lewandowsky M, editor. Handbuch der Neurologie. Erster Band: Allgemeine Neurologie, zweiter Teil. Berlin: Julius Springer; 1910. pp. 1481–515.Google Scholar
  93. Kendler KS, Schaffner KF. The dopamine hypothesis of schizophrenia: an historical and philosophical analysis. Philos Psychiatry Psychol. 2011;18:41–63.CrossRefGoogle Scholar
  94. Kety SS. Résumé: I. Biochimie. In: de Ajuriaguerra J, editor. Monoamines et système nerveux central. Symposium Bel-Air, Genève, Septembre 1961. Genève: Georg et Cie; 1962. pp. 263–8.Google Scholar
  95. King C, Voruganti LNP. What’s in a name? The evolution of the nomenclature of antipsychotic drugs. J Psychiatry Neurosci. 2002;27:168–75.PubMedPubMedCentralGoogle Scholar
  96. Kraepelin E. Über die Beeinflussung einfacher psychischer Vorgänge durch einige Arzneimittel. experimentelle Untersuchungen. Jena: Gustav Fischer; 1892.Google Scholar
  97. Kraepelin E. Klinische Psychiatrie. Psychiatrie: ein Lehrbuch für Studirende und Ärzte. Bd. 2. Leipzig: Barth; 1899.Google Scholar
  98. Kuhn R. Psychopharmakologie gestern – heute – morgen. Vortrag zur Verleihung der Hans-Prinzhorn-Medaille in Berlin am 28. Oktober 2004. Schweiz Arch Neurol Psychiatr. 2005;156:267–9.CrossRefGoogle Scholar
  99. Lader M. History of benzodiazepine dependence. J Subst Abus Treat. 1991;8:53–9.CrossRefGoogle Scholar
  100. Laignel-Lavastine M. Des troubles psychiques par perturbations des glandes à sécrétion interne. Congrès des aliénistes et neurologistes de France et des pays de langue française, XVIIIe session, Dijon, août 1908. Paris: G. Masson; 1908.Google Scholar
  101. Lambert PA, Revol L. Classification psychopharmacologique et clinique des différents neuroleptiques. Indications thérapeutiques générales dans les psychoses. Presse Med. 1960;68:1509–11.PubMedGoogle Scholar
  102. Ledermann F. Pharmacie, médicaments et psychiatrie vers 1850: le cas de Jacques-Joseph Moreau de Tours. Rev Hist Pharm. 1988;35:67–76.CrossRefGoogle Scholar
  103. Lehmann HE. Before they called it psychopharmacology. Neuropsychophrmacology. 1993;8:291–303.CrossRefGoogle Scholar
  104. Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.PubMedCrossRefGoogle Scholar
  105. Lewin L. Phantastica: die betäubenden und erregenden Genussmittel, für Ärzte und Nichtärzte. Berlin: Georg Stilke; 1924.Google Scholar
  106. Loera-Valencia R, Cedazo-Minguez A, Kenigsberg PA, Page G, Duarte AI, Giusti P, Zusso M, Robert P, Frisoni GB, Cattaneo A, Zille M, Boltze J, Cartier N, Buee L, Johansson G, Winblad B. Current and emerging avenues for Alzheimer’s disease drug targets. J Intern Med. 2019;86:398–437.CrossRefGoogle Scholar
  107. López-Muñoz F, Alamo C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Res Bull. 2009;79:130–41.PubMedCrossRefGoogle Scholar
  108. López-Muñoz F, Álamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des. 2009;15:1563–86.PubMedCrossRefGoogle Scholar
  109. López-Muñoz F, Bhatara VS, Álamo C, Cuenca E. Aproximación histórica al descubrimiento de la reserpina y su introducción en la clinica psiquiátrica. Actas Espanolas de Psiquiatria. 2004a;32:387–95.PubMedGoogle Scholar
  110. López-Muñoz F, Ucha-Udabe R, Álamo-González C. Un siglo de barbitúricos en neurología. Rev Neurol. 2004b;39:767–75.PubMedGoogle Scholar
  111. López-Muñoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry. 2005;17:113–35.PubMedCrossRefGoogle Scholar
  112. López-Muñoz F, Álamo C, García-García P. The discovery of chlordiazepoxide and the clinical introduction of benzodiazepines: half a century of anxiolytic drugs. J Anxiety Disord. 2011;25:554–62.PubMedCrossRefGoogle Scholar
  113. López-Muñoz F, Shen WW, D’Ocon P, Romero A, Álamo C. A history of the pharmacological treatment of bipolar disorder. Int J Mol Sci. 2018;19:2143.PubMedCentralCrossRefPubMedGoogle Scholar
  114. Löscher W, Rogawski MA. How theories evolved concerning the mechanism of action of barbiturates. Epilepsia. 2012;53(Suppl. 8):12–25.PubMedCrossRefGoogle Scholar
  115. Macht DI. Contributions to psychopharmacology. Johns Hopkins Hosp Bull. 1920;31:167–73.Google Scholar
  116. Maier HW. Der Kokainismus: Geschichte, Pathologie, Medizinische und behördliche Bekämpfung. Leipzig: Georg Thieme; 1926.Google Scholar
  117. Malhi GS, Byrow Y, Bassett D, Boyce P, Hopwood M, Lyndon W, Mulder R, Porter R, Singh A, Murray G. Stimulants for depression: on the up and up? Aust N Z J Psychiatry. 2016;50:203–7.PubMedCrossRefGoogle Scholar
  118. Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs. From basic science to novel clinical applications to CNS disorders. Drugs. 2010;70:287–312.PubMedCrossRefGoogle Scholar
  119. Mandrioli R, Protti M, Mercolini L. New-generation, non-SSRI antidepressants: therapeutic drug monitoring and pharmacological interactions. Part 1: SNRIs, SMSs, SARIs. Curr Med Chem. 2018;25:772–92.PubMedCrossRefGoogle Scholar
  120. Margineanu DG. A weird concept with unusual fate: nootropic drug. Revue des Questions Scientifiques. 2011;182:33–52.Google Scholar
  121. Marraccini ME, Weyandt LL, Rossi JS, Gudmundsdottir BG. Neurocognitive enhancement or impairment? A systematic meta-analysis of prescription stimulant effects on processing speed, decision-making, planning, and cognitive perseveration. Exp Clin Psychopharmacol. 2016;24:269–84.PubMedPubMedCentralCrossRefGoogle Scholar
  122. Moncrieff J. The creation of the concept of an antidepressant: an historical analysis. Soc Sci Med. 2008;66:2346–55.PubMedCrossRefGoogle Scholar
  123. Moreau de Tours J. Du hachisch et de l’aliénation mentale. Études psychologiques. Paris: Fortin, Masson & Cie; 1845.Google Scholar
  124. Mulinari S. Monoamine theories of depression: historical impact on biomedical research. J Hist Neurosci. 2012;21:366–92.PubMedCrossRefGoogle Scholar
  125. Müller T, Möhr JD. Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson’s disease: current status. Expert Opin Drug Metab Toxicol. 2019;15:429–35.PubMedCrossRefGoogle Scholar
  126. Müller U, Fletcher PC, Steinberg H. The origin of pharmacopsychology: Emil Kraepelin’s experiments in Leipzig, Dorpat and Heidelberg (1882–1892). Psychopharmacology (Berlin). 2006;184:131–8.CrossRefGoogle Scholar
  127. Murri MB, Guaglianone A, Bugliani M, Calcagno P, Respino M, Serafini G, Innamorati M, Pompili M, Amore M. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R&D. 2015;15:45–62.CrossRefGoogle Scholar
  128. Noll R. Kraepelin’s ‘lost biological psychiatry’? Autointoxication, organotherapy and surgery for dementia praecox. Hist Psychiatry. 2007;18:301–20.PubMedCrossRefGoogle Scholar
  129. Nucifora FC, Mihaljevic M, Lee BJ, Sawa A. Clozapine as a model for antipsychotic development. Neurotherapeutics. 2017;14:750–61.PubMedPubMedCentralCrossRefGoogle Scholar
  130. Onians RB. The origins of European thought about the body, the mind, the soul, the world, time, and fate. Cambridge, MA: Cambridge University Press; 1988.CrossRefGoogle Scholar
  131. Oppenheimer H. Medical and allied topics in Latin poetry. London: John Bale, Sons & Danielson; 1928.Google Scholar
  132. Page IH. Chemistry of the brain. Springfield/Baltimore: Charles C. Thomas; 1937.Google Scholar
  133. Paladin A. Recherches sur la biochimie du cerveau. Bull Soc Chim Biol. 1934;16:1193–210.Google Scholar
  134. Pare CMB, Rees L, Sainsbury MJ. Differentiation of two genetically specific types of depression by the response to anti-depressants. Lancet. 1962;2:1340–3.PubMedCrossRefGoogle Scholar
  135. Paulson GW. Historical comments on tardive dyskinesia: a neurologist’s perspective. J Clin Psychiatry. 2005;66:260–4.PubMedCrossRefGoogle Scholar
  136. Perez-Caballero L, Torres-Sanchez S, Bravo L, Mico JA, Berrocoso E. Fluoxetine: a case history of its discovery and preclinical development. Expert Opin Drug Discovery. 2014;9:567–78.CrossRefGoogle Scholar
  137. Pinel P. Traité medico-philosophique sur l’aliénation mentale. Paris: J. Ant. Brosson; 1809.Google Scholar
  138. Ramchandani D, López-Muñoz F, Álamo C. Meprobamate: tranquilizer or anxiolytic? A historical perspective. Psychiatry Q. 2006;77:43–53.CrossRefGoogle Scholar
  139. Rasmussen N. Making the first anti-depressant: amphetamine in American medicine, 1929–1950. J Hist Med Allied Sci. 2006;61:288–323.PubMedCrossRefGoogle Scholar
  140. Rasmussen N. Amphetamine-type stimulants: the early history of their medical and non-medical uses. Int Rev Neurobiol. 2015;120:9–25.PubMedCrossRefGoogle Scholar
  141. Reiter PJ. Behandlung von Dementia praecox mit Metallsalzen a. m. Walbum. I. Mangan. Vorläufige Mitteilung. Zschr f d ges Neurol u Psychiat. 1929;108:464–80.CrossRefGoogle Scholar
  142. Ring J, Grosber M, Brockow K, Bergmann K-C. Anaphylaxis. In: Bergmann K-C, Ring J, editors. History of allergy. Basel: Karger; 2014. pp. 54–61.Google Scholar
  143. Robbins TW. Pharmacological treatment of cognitive deficits in nondementing mental health disorders. Dialogues Clin Neurosci. 2019;21:301–8.PubMedPubMedCentralCrossRefGoogle Scholar
  144. Robitzek EH, Selikoff IJ, Ornstein GG. Chemotherapy of human tuberculosis with hydrazine derivatives of isonicotinic acid. Q Bull Sea View Hosp. 1952;13:27–51.PubMedGoogle Scholar
  145. Roncero C, Álvarez FJ. The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders. Expert Rev Neurother. 2014;14:849–65.PubMedCrossRefGoogle Scholar
  146. Ross S, Cole JO. Psychopharmacology. Annu Rev Psychol. 1960;11:415–38.CrossRefGoogle Scholar
  147. Rupniak NMJ, Kramer MS. NK1 receptor antagonists for depression: why a validated concept was abandoned. J Affect Disord. 2017;223:121–5.PubMedCrossRefGoogle Scholar
  148. Schatzberg AF. New approaches to managing psychotic depression. J Clin Psychiatry. 2003;64(Suppl. 1):19–23.PubMedGoogle Scholar
  149. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatr. 1965;509:509–22.CrossRefGoogle Scholar
  150. Schioldann J. ‘On periodical depressions and their pathogenesis’ by Carl Lange (1886). Hist Psychiatry. 2011;22:108–30.PubMedCrossRefGoogle Scholar
  151. Schmitz H. Die Opiumbehandlung bei Geisteskrankheiten, insbesondere bei Melancholie, ihre Geschichte, ihr heutiger Stand und eigene Erfahrungen. Allg Zschr Psychiat psych-gerichtl Med. 1925;83:92–112.Google Scholar
  152. Schneider PJ. Entwurf zu einer Heilmittellehre gegen psychische Krankheiten, oder Heilmittel in Beziehung auf psychische Krankheitsformen. Tübingen: Heinrich Laupp; 1824.Google Scholar
  153. Schou M. Lithium treatment at 52. J Affect Disord. 2001;67:21–32.PubMedCrossRefGoogle Scholar
  154. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1987;1:133–52.PubMedCrossRefGoogle Scholar
  155. Seige M. Klinische Erfahrungen mit Neuronal. Dtsch Med Wochenschr. 1912;38:1828–30.CrossRefGoogle Scholar
  156. Sertürner F. Darstellung der reinen Mohnsäure (Opiumsäure) nebst einer chemischen Untersuchung des Opiums mit vorzüglicher Hinsicht auf einen darin neu entdeckten Stoff und die dahin gehörigen Bemerkungen. Journal der Pharmacie für Ärzte, Apotheken und Chemisten. 1806;14:47–93.Google Scholar
  157. Shen WW. A history of antipsychotic drug development. Compr Psychiatry. 1999;40:407–14.PubMedCrossRefGoogle Scholar
  158. Siegel RE. Galen on psychology, psychopathology, and function and diseases of the nervous system. Basel: S. Karger; 1973.Google Scholar
  159. Somers K. Notes on rauwolfia and ancient medical writings of India. Med Hist. 1958;2:87–91.PubMedPubMedCentralCrossRefGoogle Scholar
  160. Sourkes TL. Early clinical neurochemistry of CNS-active drugs. Bromides. Mol Chem Neuropathol. 1991;14:131–42.PubMedCrossRefGoogle Scholar
  161. Sourkes TL. Early clinical neurochemistry of CNS-active drugs. Chloral hydrate. Mol Chem Neuropathol. 1992;17:21–30.PubMedCrossRefGoogle Scholar
  162. Speaker SL. From “happiness pills” to “national nightmare”: changing cultural assessment of minor tranquilizers in America, 1955–1980. J Hist Med Allied Sci. 1997;52:338–76.PubMedCrossRefPubMedCentralGoogle Scholar
  163. Steck H. Le syndrome extrapyramidal et diencéphalique au cours de traitements au largactil et ou serpasil. Ann Med Psychol. 1954;112:737–43.Google Scholar
  164. Sternbach LH. The benzodiazepine story. J Psychoactive Drugs. 1983;15:15–7.PubMedCrossRefGoogle Scholar
  165. Szökő É, Tábi T, Riederer P, Vécsei L, Magyar K. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease. J Neural Transm. 2018;125:1735–49.PubMedCrossRefGoogle Scholar
  166. Tarsy D. History and definition of tardive dyskinesia. Clin Neuropharmacol. 1983;6:91–9.PubMedCrossRefGoogle Scholar
  167. Thorner MW. Psycho-pharmacology of sodium amytal. J Nerv Ment Dis. 1935;81:161–7.CrossRefGoogle Scholar
  168. Thudichum JLW. A treatise on the chemical constitution of the brain. London: Ballière, Tindall & Cox; 1884.Google Scholar
  169. Toda M, Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep. 2007;9:329–36.PubMedCrossRefGoogle Scholar
  170. Tschupp C. Johanniskraut, Hypericum perforatum L.: vom Hexenkraut zum modernen Arzneimittel (Veröffentlichungen der Schweizerischen Gesellschaft für Geschichte der Pharmazie; 26). Brugg: Schweizerischen Gesellschaft für Geschichte der Pharmazie; 2004.Google Scholar
  171. van Enkhuizen J, Janowsky DS, Olivier B, Minassian A, Perry W, Young JW, Geyer MA. The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited. Eur J Pharmacol. 2015;753:114–26.PubMedCrossRefGoogle Scholar
  172. Vanle B, Olcott W, Jimenez J, Bashmi L, Danovitch I, IsHak WW. NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease. Transl Psychiatry. 2018;8:117.PubMedPubMedCentralCrossRefGoogle Scholar
  173. Vogt C, Vogt O. Zur Lehre der Erkrankungen des striären Systems. J Psychol Neurol. 1920;25(Suppl 3):627–846.Google Scholar
  174. Walther-Buël H. Drei Dezennien Narkotherapie. Monatsschr Psychiatr Neurol. 1953;125:718–31.PubMedCrossRefGoogle Scholar
  175. Walton M. Deep sleep therapy and Chelmsford private hospital: have we learnt anything? Australas Psychiatry. 2013;21:206–12.PubMedCrossRefGoogle Scholar
  176. Weber MM. Die „Opiumkur” in der Psychiatrie: Ein Beitrag zur Geschichte der Psychopharmakotherapie. Sudhoffs Arch. 1987;71:31–61.Google Scholar
  177. Weber MM. Die Entwicklung der Psychopharmakologie im Zeitalter der naturwissenschaftlichen Medizin Ideengeschichte eines psychiatrischen Therapiesystems. München: Urban und Vogel; 1999.Google Scholar
  178. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007;13:13–24.PubMedCrossRefGoogle Scholar
  179. Wilkins RW. Clinical usage of Rauwolfia alkaloids, including reserpine (Serpasil). Ann N Y Acad Sci. 1954;59:36–44.PubMedCrossRefGoogle Scholar
  180. Williams M. Antianxiety agents: a historical perspective. In: Meldrum BS, Williams M, editors. Current and future trends in anticonvulsant, anxiety, and stroke therapy: proceedings of a symposium held at Princeton, New Jersey, May 21–23, 1989 (Progress in clinical and biological research, 361). New York: Wiley-Liss; 1990. pp. 131–44.Google Scholar
  181. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005;11:169–82.PubMedCrossRefGoogle Scholar
  182. Wolf MA, Yassa R, Llorca PM. Complications extrapyramidales induites par les neuroleptiques. Perspectives historiques. Encephalé. 1993;19:657–61.Google Scholar
  183. Wong DT, Perry KW, Bymaster FP. The discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov. 2005;4:764–74.PubMedCrossRefGoogle Scholar
  184. Wyatt RJ, Gillin JC. The transmethylation hypothesis: a quarter of a century later. Psychiatr Ann. 1976;6:33–49.Google Scholar
  185. Yáñez M, Padín JF, Arranz-Tagarro JA, Camina M, Laguna R. History and therapeutic use of MAO-A inhibitors: a historical perspective of MAO-A inhibitors as antidepressant drug. Curr Top Med Chem. 2012;12:2275–82.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Medical Journal of AustraliaSydneyAustralia

Section editors and affiliations

  • Peter Riederer
    • 1
  1. 1.University Hospital, Center for Mental Health, Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University WuerzburgWuerzburgGermany

Personalised recommendations